Catalog No.
RHC12512
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
22D12
β-Amyloid as a new target to suppress tonic PTH hypersecretion in primary hyperparathyroidism., PMID:40492090
Soluble VCAM-1 may serve as a pharmacodynamic CSF marker to monitor BACE2 activity in non-human primates., PMID:40480341
Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis., PMID:40455292
Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life., PMID:40442822
PET imaging of TREM2 in amyloid-beta induced neuroinflammation., PMID:40434494
Discovery of an APP-selective BACE1 inhibitor for Alzheimer's disease., PMID:40399225
Co-occurrence of Down Syndrome and Multiple Sclerosis., PMID:40395918
Blockage of CCL3 with neutralizing antibody reduces neuroinflammation and reverses Alzheimer disease phenotypes., PMID:40268067
Multianalyte Nanopore Detection of Alzheimer's Biomarkers: A Label-Free Platform with Improved Sensitivity and Range., PMID:40129019
Bone marrow mesenchymal stem cells derived cytokines associated with AKT/IAPs signaling ameliorate Alzheimer's disease development., PMID:39849525
Immunohistochemical labeling of ongoing axonal degeneration 10 days following cervical contusion spinal cord injury in the rat., PMID:39753895
Acute Communication Between Microglia and Nonparenchymal Immune Cells in the Anti-Aβ Antibody-Injected Cortex., PMID:39741000
Neprilysin-Mediated Amyloid Beta Clearance and Its Therapeutic Implications in Neurodegenerative Disorders., PMID:39698259
The Features of Beta-Amyloid Phosphorylation in Alzheimer's Disease., PMID:39555172
Gene-dose-dependent reduction of Fshr expression improves spatial memory deficits in Alzheimer's mice., PMID:39548323
Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy., PMID:39504519
[Effects of JAL-TA9 on cognitive deficits in Alzheimer's disease model mouse]., PMID:39496415
The Type 1 Diabetes T Cell Receptor and B Cell Receptor Repository in the AIRR Data Commons: a practical guide for access, use and contributions through the Type 1 Diabetes AIRR Consortium., PMID:39467874
Molecular Mechanisms Underlying Amyloid Beta Peptide Mediated Upregulation of Vascular Cell Adhesion Molecule-1 in Alzheimer Disease., PMID:39455283
Autoantibodies to BACE1 promote Aβ accumulation and neurodegeneration in Alzheimer's disease., PMID:39448400
Blockade of brain alkaline phosphatase efficiently reduces amyloid-β plaque burden and associated cognitive impairment., PMID:39438925
Low to moderate ethanol exposure reduces astrocyte-induced neuroinflammatory signaling and cognitive decline in presymptomatic APP/PS1 mice., PMID:39402264
CRM197-scaffolded vaccines designed by epitope grafting ameliorate cognitive decline in an Alzheimer's disease model., PMID:39401639
Contactin-4 suppresses antitumor T cell responses by engaging amyloid precursor protein., PMID:39392894
Serological Responses to Target Streptococcus pyogenes Vaccine Antigens in Patients With Proven Invasive β-Hemolytic Streptococcal Infections., PMID:39383256
A guide to selecting high-performing antibodies for amyloid-beta precursor protein for use in Western Blot, immunoprecipitation and immunofluorescence., PMID:39359612
Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab., PMID:39348937
Osmundacetone ameliorates Alzheimer's-like pathologies by inhibiting β-amyloid fibrillation, oxidative damage and neuroinflammation in APP/PS1 transgenic mice., PMID:39332101
ADAM10 isoforms: Optimizing usage of antibodies based on protein regulation, structural features, biological activity and clinical relevance to Alzheimer's disease., PMID:39173916
Neocortical cholinergic pathology after neonatal brain injury is increased by Alzheimer's disease-related genes in mice., PMID:39111704
Recent Insights into the Neurobiology of Alzheimer's Disease and Advanced Treatment Strategies., PMID:39102108
Investigation of the Impact of the H310A FcRn Region Mutation on 89Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody., PMID:39093482
Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer's disease., PMID:39085976
A Framework for Best Practices and Readiness in the Advent of Anti-Amyloid Therapy for Early Alzheimer's Disease in Asia., PMID:39058448
Interplay between glypican-1, amyloid-β and tau phosphorylation in human neural stem cells., PMID:38992568
Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease., PMID:38891941
The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling., PMID:38888964
Amino-terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains., PMID:38867123
Rapidly reversible persistent long-term potentiation inhibition by patient-derived brain tau and amyloid ß proteins., PMID:38853565
Multicolor, Cell-Impermeable, and High Affinity BACE1 Inhibitor Probes Enable Superior Endogenous Staining and Imaging of Single Molecules., PMID:38842406
Aβ42 and ROS dual-targeted multifunctional nanocomposite for combination therapy of Alzheimer's disease., PMID:38783363
Multiple system atrophy with amyloid-β-predominant Alzheimer's disease neuropathologic change., PMID:38712319
Effect of Regulation of Chemerin/Chemokine-like Receptor 1/Stimulator of Interferon Genes Pathway on Astrocyte Recruitment to Aβ Plaques., PMID:38673909
Divergent Age-Dependent Conformational Rearrangement within Aβ Amyloid Deposits in APP23, APPPS1, and AppNL-F Mice., PMID:38652895
Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody., PMID:38634473
Identification and Analysis of Axolotl Homologs for Proteins Implicated in Human Neurodegenerative Proteinopathies., PMID:38540368
Alzheimer's drugs, APPlication for Down syndrome?, PMID:38513771
Modulation of hippocampal protein expression by a brain penetrant biologic TNF-α inhibitor in the 3xTg Alzheimer's disease mice., PMID:38500108
Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia., PMID:38485063
A novel mouse model for N-terminal truncated Aβ2-x generation through meprin β overexpression in astrocytes., PMID:38480559
For research use only. Not for human or drug use.
